Coordinatore | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Organization address
address: BATIMENT CE 3316 STATION 1 contact info |
Nazionalità Coordinatore | Switzerland [CH] |
Sito del progetto | http://www.memstick.org/ |
Totale costo | 4˙138˙676 € |
EC contributo | 2˙970˙372 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2007-A |
Funding Scheme | CP-FP |
Anno di inizio | 2008 |
Periodo (anno-mese-giorno) | 2008-02-01 - 2011-04-30 |
# | ||||
---|---|---|---|---|
1 |
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Organization address
address: BATIMENT CE 3316 STATION 1 contact info |
CH (LAUSANNE) | coordinator | 0.00 |
2 |
AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS
Organization address
address: CALLE SERRANO 117 contact info |
ES (MADRID) | participant | 0.00 |
3 |
ENKAM PHARMACEUTICALS A/S
Organization address
address: "Fruebjergvej, 3" contact info |
DK (COPENHAGEN) | participant | 0.00 |
4 |
INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK
Organization address
address: UL. LUDWIKA PASTEURA 3 contact info |
PL (WARSZAWA) | participant | 0.00 |
5 |
KATHOLIEKE UNIVERSITEIT LEUVEN
Organization address
address: Oude Markt 13 contact info |
BE (LEUVEN) | participant | 0.00 |
6 |
MAX PLANCK GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.
Organization address
address: Hofgartenstrasse 8 contact info |
DE (MUENCHEN) | participant | 0.00 |
7 |
NEOLOCH PHARMACEUTICALS APS
Organization address
address: Tjornekrogen 5 contact info |
DK (GENTOFTE) | participant | 0.00 |
8 |
SCIPROM SARL
Organization address
address: RUE DU CENTRE 70 contact info |
CH (Saint-Sulpice) | participant | 0.00 |
9 |
THE OPEN UNIVERSITY
Organization address
address: WALTON HALL contact info |
UK (MILTON KEYNES) | participant | 0.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Memory loss is a central symptom in different diseases, and represents a significant social and economic burden for a large percentage of European citizens. The molecular and neurobiological bases of memory deficits are largely unknown and there are currently no drugs available that can markedly decelerate or prevent memory decline. To address this major problem, this project will investigate the role of novel synaptic cell adhesion molecules (CAMs) in memory loss, and the therapeutic value of targeting these CAMs to restore memory function and associated neurobiological mechanisms at the synaptic level. The selection of novel synaptic CAMs is based on (1) recent evidence showing that they can recruit the synaptic machinery and form synapses; (2) the implication of CAMs, in general, in synaptic plasticity and memory, and (3) a direct link established between synaptic remodelling and memory formation. We have assembled a multidisciplinary consortium including excellent European researchers in this field, covering a wide range of structural, biochemical, electrophysiological and behavioural expertise. To understand memory loss, three domains have been selected as among the most prominent and widespread disease domains affecting memory and quality of life in our society: psychiatric disorders, the neurodegenerative disorder of Alzheimer's disease, stress and aging. For each disease domain, specific and validated animal models will be used to investigate memory loss on molecular, subcellular, cellular and functional levels. Our approach will result in the preclinical development and validation of mimetic peptides for novel synaptic CAMs as potential drug candidates to treat memory deficits or prevent memory decline. The current proposal offers the groundbreaking possibility to raise the bar in memory research by targeting novel molecules and developing effective drugs to treat memory disturbances based on their biological mechanism.'
Quantum Dot-Based Highly Sensitive Immunoassays for Multiplexed Diagnostics of Alzheimer's Disease
Read MoreDevelopment of a European Implementation Score for measuring implementation of research into healthcare practice using vascular disease as an example
Read MoreUnderstanding and fighting metastasis by modulating the tumour microenvironment through interference with the protease network
Read More